Close
Nordic 9Nordic 9

Atlas Venture (investor - Venture Capital)

United States atlasventure.com
See something wrong or missing? Let us know
Offices:New York

Atlas Venture is a biotech seed and early stage venture investor from USA.

Average round investment:84.45M USD
Average number per year:1.0
Distribution: 2024 (1)2023 (1)2022 (1)
Portfolio companies: United Kingdom Pheon TherapeuticsItaly AAVantgarde Bio
Mostly invests in: United Kingdom United Kingdom (2) Biotech (3)

3 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Atlas Venture mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Atlas Venture

Name Criteria
China GT Healthcare Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Cowen Healthcare Investments
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Switzerland HBM Healthcare Investments
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Italy
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United States What If Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United States Patient Square Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States Bristol-Myers Squibb
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.6
  • Active last 12 months: Yes
United States Foresite Capital
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.3
  • Active last 12 months: Yes
United Kingdom Medicxi
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Evotec AG
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Abingworth
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top